<p>你可能会认为，<strong>Lifecore Biomedical, Inc.</strong>（纳斯达克代码：LFCR）以 2.4 倍的市销率（&#34;P/S&#34;）值得关注，因为几乎一半的美国生命科学公司市销率超过 3.7 倍，甚至超过 7 倍的市销率也并不罕见。然而，我们需要深入挖掘一下，以确定这种较低的市销率是否有合理的依据。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现的各个方面进行研发。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p>查看我们对 Lifecore Biomedical 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/30668-ps-multiple-vs-industry-1-dark-2/1768904675811?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/30668-ps-multiple-vs-industry-1-dark-2/1768904675811"/></p>
<p>纳斯达克 GS:LFCR 市销率与行业比较 2026 年 1 月 20 日</p>
<h3>Lifecore Biomedical 最近的表现如何？</h3>
<p>最近，Lifecore Biomedical 的表现并不理想，因为其收入增长速度低于大多数其他公司。似乎许多人预计这种乏善可陈的收入表现将持续下去，这抑制了市销率的增长。如果是这样的话，现有股东可能会对股价未来的走势感到失望。</p>
<p>如果你想了解分析师对未来的预测，可以查看我们关于 Lifecore Biomedical 的 <strong>免费</strong> 报告。</p>
<h2>收入增长指标告诉我们关于低市销率的什么？</h2>
<p>为了证明其市销率的合理性，Lifecore Biomedical 需要产生低迷的增长，且增长速度落后于行业。</p>
<p>回顾过去，我们看到该公司在过去一年几乎没有可言的收入增长。尽管如此，得益于早期的增长，收入在三年前的基础上总共提升了 16%。因此，我们认为该公司在收入增长方面的表现是喜忧参半的。</p>
<p>展望未来，根据跟踪该公司的四位分析师的预测，收入预计在未来三年内每年增长 5.8%。而行业预计每年将实现 6.5% 的增长，因此该公司的收入表现与行业相当。</p>
<p>根据这些信息，我们觉得奇怪的是，Lifecore Biomedical 的市销率低于行业水平。可能大多数投资者并不相信该公司能够实现未来的增长预期。</p>
<h2>最后的总结</h2>
<p>一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
<p>我们看到，Lifecore Biomedical 目前的市销率低于预期，因为其预测增长与更广泛的行业一致。低市销率可能表明市场对收入增长预期的质疑。然而，如果你同意分析师的预测，你可能能够以有吸引力的价格买入该股票。</p>
<p>在你形成观点之前，我们发现了 <strong>Lifecore Biomedical 的 2 个警示信号</strong>，你应该注意。</p>
<p>重要的是要 <strong>确保你寻找的是一家优秀的公司，而不仅仅是你遇到的第一个想法。</strong> 因此，如果持续盈利能力符合你对优秀公司的定义，可以查看这个 <strong>免费</strong> 的有趣公司名单，这些公司最近的盈利增长强劲且市盈率较低。</p>

LFCR

<p>Lifecore Biomedical, Inc.（纳斯达克代码：LFCR）的市销率为 2.4 倍，低于行业平均水平 3.7 倍，显示出潜在的投资机会。尽管在三年内收入增长了 16%，但近期增长乏力，预计年增长率为 5.8%，而行业平均为 6.5%。较低的市销率表明市场对公司未来增长的怀疑。如果投资者与分析师的预测一致，可能会发现价值，但由于已识别的警示信号，建议保持谨慎</p>

<p>You may think that with a price-to-sales (or &#34;P/S&#34;) ratio of 2.4x <strong>Lifecore Biomedical, Inc.</strong> (NASDAQ:LFCR) is a stock worth checking out, seeing as almost half of all the Life Sciences companies in the United States have P/S ratios greater than 3.7x and even P/S higher than 7x aren't out of the ordinary. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.</p>
<div class="lb-trans"><p>你可能会认为，<strong>Lifecore Biomedical, Inc.</strong>（纳斯达克代码：LFCR）以 2.4 倍的市销率（&#34;P/S&#34;）值得关注，因为几乎一半的美国生命科学公司市销率超过 3.7 倍，甚至超过 7 倍的市销率也并不罕见。然而，我们需要深入挖掘一下，以确定这种较低的市销率是否有合理的依据。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现的各个方面进行研发。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p>Check out our latest analysis for Lifecore Biomedical</p>
<div class="lb-trans"><p>查看我们对 Lifecore Biomedical 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/30668-ps-multiple-vs-industry-1-dark-2/1768904675811" alt="" original-src="https://images.simplywall.st/asset/chart/30668-ps-multiple-vs-industry-1-dark-2/1768904675811"/></p>
<p>NasdaqGS:LFCR Price to Sales Ratio vs Industry January 20th 2026</p>
<div class="lb-trans"><p>纳斯达克 GS:LFCR 市销率与行业比较 2026 年 1 月 20 日</p>
</div><h3>How Has Lifecore Biomedical Performed Recently?</h3>
<div class="lb-trans"><h3>Lifecore Biomedical 最近的表现如何？</h3>
</div><p>Recent times haven't been great for Lifecore Biomedical as its revenue has been rising slower than most other companies. It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.</p>
<div class="lb-trans"><p>最近，Lifecore Biomedical 的表现并不理想，因为其收入增长速度低于大多数其他公司。似乎许多人预计这种乏善可陈的收入表现将持续下去，这抑制了市销率的增长。如果是这样的话，现有股东可能会对股价未来的走势感到失望。</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on Lifecore Biomedical.</p>
<div class="lb-trans"><p>如果你想了解分析师对未来的预测，可以查看我们关于 Lifecore Biomedical 的 <strong>免费</strong> 报告。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增长指标告诉我们关于低市销率的什么？</h2>
</div><p>In order to justify its P/S ratio, Lifecore Biomedical would need to produce sluggish growth that's trailing the industry.</p>
<div class="lb-trans"><p>为了证明其市销率的合理性，Lifecore Biomedical 需要产生低迷的增长，且增长速度落后于行业。</p>
</div><p>Taking a look back first, we see that there was hardly any revenue growth to speak of for the company over the past year. Regardless, revenue has managed to lift by a handy 16% in aggregate from three years ago, thanks to the earlier period of growth. So it appears to us that the company has had a mixed result in terms of growing revenue over that time.</p>
<div class="lb-trans"><p>回顾过去，我们看到该公司在过去一年几乎没有可言的收入增长。尽管如此，得益于早期的增长，收入在三年前的基础上总共提升了 16%。因此，我们认为该公司在收入增长方面的表现是喜忧参半的。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 5.8% per annum during the coming three years according to the four analysts following the company. With the industry predicted to deliver 6.5% growth each year, the company is positioned for a comparable revenue result.</p>
<div class="lb-trans"><p>展望未来，根据跟踪该公司的四位分析师的预测，收入预计在未来三年内每年增长 5.8%。而行业预计每年将实现 6.5% 的增长，因此该公司的收入表现与行业相当。</p>
</div><p>With this information, we find it odd that Lifecore Biomedical is trading at a P/S lower than the industry. It may be that most investors are not convinced the company can achieve future growth expectations.</p>
<div class="lb-trans"><p>根据这些信息，我们觉得奇怪的是，Lifecore Biomedical 的市销率低于行业水平。可能大多数投资者并不相信该公司能够实现未来的增长预期。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最后的总结</h2>
</div><p>Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>一般来说，我们倾向于将市销率的使用限制在评估市场对公司整体健康状况的看法上。</p>
</div><p>We've seen that Lifecore Biomedical currently trades on a lower than expected P/S since its forecast growth is in line with the wider industry. The low P/S could be an indication that the revenue growth estimates are being questioned by the market. However, if you agree with the analysts' forecasts, you may be able to pick up the stock at an attractive price.</p>
<div class="lb-trans"><p>我们看到，Lifecore Biomedical 目前的市销率低于预期，因为其预测增长与更广泛的行业一致。低市销率可能表明市场对收入增长预期的质疑。然而，如果你同意分析师的预测，你可能能够以有吸引力的价格买入该股票。</p>
</div><p>Before you settle on your opinion, we've discovered <strong>2 warning signs for Lifecore Biomedical</strong> that you should be aware of.</p>
<div class="lb-trans"><p>在你形成观点之前，我们发现了 <strong>Lifecore Biomedical 的 2 个警示信号</strong>，你应该注意。</p>
</div><p>It's important to <strong>make sure you look for a great company, not just the first idea you come across.</strong> So if growing profitability aligns with your idea of a great company, take a peek at this <strong>free</strong> list of interesting companies with strong recent earnings growth (and a low P/E).</p>
<div class="lb-trans"><p>重要的是要 <strong>确保你寻找的是一家优秀的公司，而不仅仅是你遇到的第一个想法。</strong> 因此，如果持续盈利能力符合你对优秀公司的定义，可以查看这个 <strong>免费</strong> 的有趣公司名单，这些公司最近的盈利增长强劲且市盈率较低。</p>
</div>

Lifecore Biomedical, Inc.（纳斯达克股票代码：LFCR）的低市销率可能意味着一个投资机会